NAS:FOLD (USA) Also trade in: Germany UK

Amicus Therapeutics Inc

$ 12.34 -0.11 (-0.88%)
Volume: 596,863 Avg Vol (1m): 2,965,691
Market Cap $: 3.09 Bil Enterprise Value $: 2.85 Bil
P/E (TTM): 0.00 P/B: 5.90
Earnings Power Value -12.9
Net Current Asset Value 0.8
Tangible Book 1.08
Projected FCF -5.38
Median P/S Value 19.77
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 2.11
Cash-To-Debt ranked lower than
66.60% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
FOLD: 2.11
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 1.43, Med: 21.36, Max: 10000
Current: 2.11
1.43
10000
Equity-to-Asset 0.59
Equity-to-Asset ranked lower than
50.98% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
FOLD: 0.59
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.28, Med: 0.49, Max: 0.84
Current: 0.59
0.28
0.84
Debt-to-Equity 0.46
Debt-to-Equity ranked lower than
52.20% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
FOLD: 0.46
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -0.05, Med: 0.05, Max: 0.94
Current: 0.46
-0.05
0.94
Debt-to-EBITDA -0.53
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
FOLD: -0.53
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -1, Med: -0.28, Max: -0.01
Current: -0.53
-1
-0.01
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.52
DISTRESS
GREY
SAFE
Beneish M-Score -1.21
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -203.21%
WACC 12.36%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -322.57
Operating Margin ranked lower than
63.51% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
FOLD: -322.57
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -17133.06, Med: -571.03, Max: -9.06
Current: -322.57
-17133.06
-9.06
Net Margin % -386.18
Net Margin ranked lower than
67.55% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
FOLD: -386.18
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -16427.82, Med: -769.03, Max: -10.2
Current: -386.18
-16427.82
-10.2
ROE % -91.61
ROE ranked lower than
62.99% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
FOLD: -91.61
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -103.74, Med: -81.22, Max: -9.19
Current: -91.61
-103.74
-9.19
ROA % -51.28
ROA ranked lower than
52.31% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
FOLD: -51.28
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -55.51, Med: -44.78, Max: -6.13
Current: -51.28
-55.51
-6.13
ROC (Joel Greenblatt) % -1866.14
ROC (Joel Greenblatt) ranked lower than
77.51% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
FOLD: -1866.14
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -4575.5, Med: -1938.99, Max: -134.99
Current: -1866.14
-4575.5
-134.99
3-Year Total EBITDA Growth Rate -35.80
3-Year EBITDA Growth Rate ranked lower than
85.79% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
FOLD: -14
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -81.7, Med: 9.75, Max: 85.7
Current: -14
-81.7
85.7
3-Year EPS w/o NRI Growth Rate -16.10
3-Year EPS w/o NRI Growth Rate ranked lower than
79.95% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
FOLD: -16.1
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -54.5, Med: 10, Max: 85.2
Current: -16.1
-54.5
85.2

» FOLD's 30-Y Financials

Financials (Next Earnings Date: 2019-08-07)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:FOLD

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:IMMU XKRX:084990 NAS:AGIO NAS:MRTX NAS:ICPT SZSE:002821 NYSE:BHVN XSWX:IDIA HKSE:01877 NAS:ARNA XBRU:TUB NAS:RETA XMAD:ALM HKSE:00570 NAS:FGEN SHSE:600201 TSE:4974 OCSE:ALK B SHSE:603233 NAS:QURE
Traded in other countries AM6.Germany 0HF9.UK
Address 1 Cedar Brook Drive, Cranbury, NJ, USA, 08512
Amicus Therapeutics Inc is a global biotechnology company that aims to treat rare and orphan diseases. The company's strategy focuses on global capacity with an international infrastructure, late-stage product acquisition, and biologics manufacturing. Amicus leverages its pharmacological technology to develop treatments for human genetic diseases by targeting mutated proteins. The company utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products.

Ratios

Current vs industry vs history
PB Ratio 5.90
PB Ratio ranked lower than
57.59% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
FOLD: 5.9
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.87, Med: 3.62, Max: 14.52
Current: 5.9
0.87
14.52
PS Ratio 22.35
PS Ratio ranked lower than
72.04% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
FOLD: 22.35
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.85, Med: 35.75, Max: 4540
Current: 22.35
0.85
4540
EV-to-EBIT -7.25
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
FOLD: -7.25
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -16.3, Med: -3.3, Max: 2.1
Current: -7.25
-16.3
2.1
EV-to-EBITDA -7.33
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
FOLD: -7.33
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -16.6, Med: -3.5, Max: 4.1
Current: -7.33
-16.6
4.1
EV-to-Revenue 26.28
EV-to-Revenue ranked lower than
67.57% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
FOLD: 26.28
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -0.3, Med: 27.35, Max: 4964.1
Current: 26.28
-0.3
4964.1
Current Ratio 7.33
Current Ratio ranked higher than
78.40% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
FOLD: 7.33
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 2.39, Med: 7.19, Max: 21.6
Current: 7.33
2.39
21.6
Quick Ratio 7.21
Quick Ratio ranked higher than
78.49% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
FOLD: 7.21
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 2.35, Med: 7.19, Max: 21.6
Current: 7.21
2.35
21.6
Days Inventory 178.34
Days Inventory ranked lower than
76.72% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
FOLD: 178.34
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 164.88, Med: 235.27, Max: 748.4
Current: 178.34
164.88
748.4
Days Sales Outstanding 77.17
Days Sales Outstanding ranked lower than
65.87% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
FOLD: 77.17
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 63.94, Med: 90.7, Max: 1088.97
Current: 77.17
63.94
1088.97
Days Payable 1.00
Days Payable ranked lower than
96.64% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
FOLD: 1
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 1, Med: 460.46, Max: 5654.65
Current: 1
1
5654.65

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -14.10
3-Year Share Buyback Rate ranked lower than
61.84% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
FOLD: -14.1
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -317.5, Med: -30.9, Max: -14.1
Current: -14.1
-317.5
-14.1

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 11.45
Price-to-Tangible-Book ranked lower than
69.24% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
FOLD: 11.45
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.96, Med: 4.03, Max: 145.22
Current: 11.45
0.96
145.22
Price-to-Median-PS-Value 0.63
Price-to-Median-PS-Value ranked higher than
52.06% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
FOLD: 0.63
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.03, Med: 0.93, Max: 101.07
Current: 0.63
0.03
101.07
Earnings Yield (Joel Greenblatt) % -13.76
Earnings Yield (Greenblatt) ranked lower than
67.25% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
FOLD: -13.76
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -30590.6, Med: -29.7, Max: 844.5
Current: -13.76
-30590.6
844.5

More Statistics

Revenue (TTM) (Mil) $ 108.6
EPS (TTM) $ -2.14
Beta 1.78
Volatility % 39.98
52-Week Range $ 8.27 - 17.62
Shares Outstanding (Mil) 189.38

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y